NEW YORK — (BUSINESS WIRE) — $CROX #CROX — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Crocs, Inc. (“Crocs” or “the Company”) (NASDAQ: CROX) and
Law goes into effect requiring the ‘Do Not Flush’ symbol on baby wipes, other wet wipes not meant for flushing LANSING, Mich. — (BUSINESS WIRE) — #DoNotFlush — Starting Feb. 1, the new Michigan law requires baby wipes, surface cleaning
Rebecca W. Flemer, M.S., Historic Preservation, University of Pennsylvania, will share research from her work life with historic gardens on landscaping and gardens of the 1820’s at a special program, Saturday, Feb. 22, at 2 p.m. at the Discovery Center at Point
FARMINGDALE, N.J. — (BUSINESS WIRE) — Cherry Hill Mortgage Investment Corporation (the “Company” or “CHMI”) (NYSE: CHMI) Tuesday announced the estimated Federal income tax treatment of the Company’s 2024 distributions on its common and preferred stock, as described below. Shareholders are encouraged
SAN FRANCISCO & BEDMINSTER, N.J. — (BUSINESS WIRE) — Swander Pace Capital (“SPC”) is pleased to announce the following promotions recognizing each employee’s significant and long-term contribution to the organization. Alex Litt has been promoted to Managing Director. Alex joined
Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval brings Daiichi Sankyo and AstraZeneca’s ENHERTU to an earlier HR positive treatment setting and broadens the patient
Toronto Pearson route begins in May TORONTO — (BUSINESS WIRE) — Porter Airlines is expanding its footprint in New York with the launch of new year-round services to LaGuardia Airport (LGA). Starting May 1, 2025, up to three daily roundtrip flights will
EWING, N.J. — (BUSINESS WIRE) — Cenlar FSB, the nation’s leading mortgage loan subservicer, announced Monday the promotion of Tom Donatacci to Senior Vice President, Chief Client Officer, overseeing Business Development and Client Management. A recognized and highly accomplished leader in the
Patients experienced a 38% reduction in the risk of disease progression or death when treated with Opdivo plus Yervoy versus Opdivo monotherapy across all lines of therapy at median 47 months of follow-up Late-breaking data presented in oral session at the 2025